
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc., a clinical-stage biotechnology firm, operates with a promising Enhanced Delivery Oligonucleotide platform that significantly improves the therapeutic potential of oligonucleotides for severe neuromuscular and neurologic diseases. Analysts highlight a substantial upside potential for PepGen's stock, currently valued around $4 per share, particularly contingent on forthcoming multi-dose data demonstrating a positive risk/benefit profile. Notably, PepGen's 53.7% splicing correction stands out as the highest reported in the DM1 space, which may provide evidence of substantial efficacy, potentially driving improved muscle performance in patients upon repeat dosing.
Bears say
The financial outlook for PepGen Inc is characterized by a $1 decrease in the target price to $8 per share, reflecting challenges in maintaining favorable market valuation despite promising preclinical data. The company's discounted market capitalization appears increasingly anachronistic, particularly in contrast to competitors like Dyne, which are better positioned in terms of regulatory momentum and broad therapeutic applications. Additionally, significant risks loom over the company's operations, as failure to execute commercially or to secure access to capital markets may lead to detrimental delays or even termination of crucial development campaigns.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares